BACKGROUND: Brain metastases are rare in @entity1 with @entity14 , but the incidence is expected to rise due to prolonged survival resulting from more effective regimens including anti- @entity470 and anti-angiogenic antibodies. Because of the potential fear of @entity932 , @entity1 with colorectal brain metastases have been excluded from clinical trials involving bevacizumab or aflibercept. @entity1 : Five @entity1 with colorectal brain metastases treated with bevacizumab-containing chemotherapy regimen following either neurosurgery, radiosurgery, or whole-brain radiotherapy were identified between 2009 and 2014. The clinicopathological data and outcomes for these @entity1 were reviewed. RESULTS: Mean time to disease progression concerning brain metastases was 14.8  months (range 5-25). Overall survival was 26.2  months (range 7-42  months) and overall survival since diagnosis of brain metastases was 20.6  month (7-42). Best response was a partial response in two and a stable disease in three @entity1 . Treatment-related adverse events were mild @entity101 (grade 1), @entity294 (grade 1), and fatigue (grade 1). No @entity932 was observed. CONCLUSION: Bevacizumab in combination with chemotherapy is a feasible option for palliative treatment of @entity1 with @entity14 with a good safety profile.

Bevacizumab in Combination with Chemotherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial hemorrhage'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity470 :: ('1956', 'Gene') :: ['EGF-receptor'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal brain metastasis', 'colorectal cancer']
@entity14 :: (MESH:D015179,Disease) :: ['Colorectal Brain Metastasis']
